Background The hepatitis C virus may lead to cirrhosis, liver cancer, liver transplant, and increased mortality. With standard treatment peginterferon-alpha and ribavirin (PR), sustained viral response (SVR) was less than 50 %. SVR rates improve greatly when PR is combined with telaprevir or boceprevir.
Introduction
The global prevalence of hepatitis C virus (HCV) infections is 2-3 %, corresponding to 130-170 million seropositive people worldwide [1] . A recent literature review [2] reported that the estimated prevalence of HCV infection in Europe ranges from 0.4 % in Sweden (300,000) to over 5.6 % in Italy (3.1 million). HCV is one of the leading causes of cirrhosis and hepatocellular carcinoma (HCC) in Western countries [3] , with 60-70 % of chronically infected people developing chronic liver disease, 5-20 % cirrhosis, and 1-5 % dying from cirrhosis or liver cancer [4] . In the Netherlands, the estimated sero-prevalence of HCV in the general population ranges between 0.1 and 0.4 % (16,487-66,000 individuals 1 ) [5, 6] . Because of its asymptomatic nature, patients are diagnosed with various levels of the disease: mild, moderate, or severe [7] . Effective treatment prevents disease progression and even improves survival, reducing liver-related morbidity among other things [8, 9] .
HCV is highly heterogeneous, with eleven genotypes (designated 1-11); genotype 1 being the most common, accounting for approximately 60 % of global infections [3] . In Northwest-Europe and especially in the Netherlands, genotype 1 has the highest prevalence at 45-50 % of HCV patients [10, 11] . Genotype 1 is the most difficult to treat. The combination therapy peginterferon-ribavirin (PR), the former standard HCV treatment, results in sustained clearance of HCV-RNA (reported as sustained virological response [SVR] ) in just over half of patients [12] and takes 24-48 weeks to treat. Higher SVR, shorter treatment and better safety profiles will improve patients' compliance and drive the development of new antiviral agents [11] .
A review of annual HCV-related costs (year 2010) showed that the median cost of liver transplants among numerous developed countries was estimated at US$139,070, HCC at US$15,310, decompensated cirrhosis at US$14,660, compensated cirrhosis at US$820, and mild to moderate chronic hepatitis C at US$280 (US$90-US$1,860) [13] . In the Netherlands, cost of liver transplantation amounted to US$166,040 (US$137,350-US$181,730) [13] . Therefore, avoiding HCV long-term complications will improve patient lives as well as save a lot of future costs to the healthcare payer and therefore society.
Two new antiviral agents, telaprevir and boceprevir, both targeting the NS3-NS4 protease complex, have been developed and are available for use in clinical practice. Randomised controlled trials (RCTs), namely ADVANCE (A Phase III Study of Telaprevir in Combination With Pegasys Ò and Copegus Ò in Treatment-Naïve Subjects With Genotype 1 HCV) for telaprevir [13] and SPRINT-2 (Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1) for boceprevir [15] , showed that telaprevir-peginterferon-ribavirin (TPR) and boceprevir-peginterferon-ribavirin (BPR) lead to SVR in about 67-74 % of treatment-naïve patients. REALIZE (A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment) for telaprevir [16] and RESPOND-2 (Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin) for boceprevir [17] trials showed that TPR and BPR led to SVR in about 65 % of TE patients; SVR rates varied according to prior treatment response.
The cost effectiveness of telaprevir has been reported several times in the literature, using similar models [18] [19] [20] [21] [22] , in the US, the UK and Italy. While effectiveness is possibly not very country-specific (although there are virus genotype differences across the countries), the economics of healthcare varies greatly from one country to another. Cost of healthcare services is known to be much higher in the US than in the UK and this of course impacts on the incremental cost-effectiveness ratio (ICER). Moreover, costs of interest in the cost-effectiveness decision-making process are not the same in each country. The UK does not consider gain/loss of productivity transfer to the NHS (i.e., they do not include indirect costs in their analysis) while the Netherlands does (a very important point in the case of a chronic disease in a relatively young patient group with a high level of impairment). Lastly, the collective willingness to pay to access health goods is not the same in each country and therefore, with the same cost-effectiveness ratio, the decision might be different from one country to another. Because of these major differences, cost-effectiveness analysis should be country specific. Therefore, it is of importance to have access to published cost-effectiveness analyses on the same treatment from a couple of different jurisdictions in order to depict the potential variation in the cost effectiveness of a novel treatment on the basis of major variations in countries' basic assumptions underlying such analyses. In this light, the societal perspective applied in the Netherlands, including indirect costs and productivity losses in the cost-utility analysis (CUA), could well be considered the most comprehensive approach. Therefore, the objective of our research was to determine the ICER of TPR compared with PR and BPR in a Dutch CUA on the management of HCV in treatmentnaïve (TN) and treatment-experienced (TE) patients.
Methods

Model Structure
A Markov model was developed to compare the costs and utilities of TPR, PR and BPR in TN and TE patients. The model was developed using Excel 2007 (Microsoft Inc). The time horizon was life-long, depicting the chronic nature of the disease, as recommended by the Dutch pharmacoeconomic guidelines [24] , and the cycle duration was 1 year, corresponding to the treatment duration.
This model was initially developed by Bennett et al. [25] , and adapted by the Scottish Health Purchasing Information Centre (SHPIC) and Canadian Agency for Drugs and Technologies in Health (CADTH) [26] . The model consisted of 14 health states (Fig. 1) . Patients entered the model in three severity stages: mild, moderate, or compensated cirrhosis. After receiving one course of antiviral treatment, patients moved from their severity stage to the SVR health states if they responded to the treatment. Patients in the mild and moderate HCV states with an SVR were assumed to no longer progress to a more severe disease stage [27] . Cirrhotic patients achieving an SVR could still progress to HCC and/or liver transplantation, but not to decompensated cirrhosis [28] . Patients not achieving SVR progressed from mild to moderate disease and from moderate to compensated cirrhosis, according to the natural evolution of HCV. The model states and their relations were confirmed by hepatitis C experts (foreign and Dutch).
Transition probabilities are reported in [14] . The TE cohort entered the model at the age of 50 years and was stratified according to the previous treatment response: relapsers, partial responders and null responders, using REALIZE [16] prevalence rates. Null responders were not included in boceprevir trials. Treatment discontinuation and stopping rules came from these RCTs as well.
Note that a panel of three experts was selected based on their experience in the field of hepatitis C treatment, a scientific focus and representativeness for physicians in the Netherlands. The experts were consulted independently and were consulted to validate several aspects of the model as outlined above and hereunder.
Treatment Regimen
The following three treatment regimens were evaluated: The stopping rules leading to treatment discontinuation for all patients were: (i) HCV-RNA [1,000 IU/mL at week 4 or \2 log genotype 10 decrease in HCV-RNA at week 12, and (ii) undetectable HCV-RNA at weeks 24, 28, 36 and 40.
Natural Hepatitis Evolution Estimates
The health states in the model were the same for TN and TE patients. The main data sources for the transition probabilities describing the natural evolution of HCV specific to age and severity group came from NICE reports [28, 29] . The probability of having liver transplantation was based on a Dutch publication (11 %) [30] .
In the Netherlands, the estimated cirrhosis mortality rates for the years 2000-2002 were 4.4 per 100,000 men and 2.33 per 100,000 women [31] . The estimated hepatocellular cancer mortality rates for the years 2000-2004 were 1.05 per 100,000 males and 0.33 per 100,000 females compared with 1.38 and 0.36 in the UK, respectively [31] . The ratio between the UK and the Netherlands is used to update the Shepherd et al. [28] mortality rates that were based on the UK. The % of males and females were taken from the clinical trials conducted with telaprevir. Thus, in TN patients there were 59 % of males (ADVANCE) and in TE this was 68 % (REALIZE) [32] . The liver cancer mortality rate (not exclusively HCC), for the period 2005-2008, was 4.1 per 100,000 men and 2.1 per 100,000 women [32] . Lastly, Dutch general mortality rates were used [33].
Treatment Strategy Effectiveness and Safety
In the absence of a head-to-head comparison between telaprevir and boceprevir at the time of the model development, a meta-analysis [34] was conducted using a mixed treatment comparison (MTC) ( Table 2) for TN [14, 15, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] and TE [16, 17, 41, 42] patients. Out of this study, the median odds ratio (OR) was derived. The MTC analysis reported a higher SVR rate for TPR over PR and BPR, both in TN and in TE patients, irrespective of their previous treatment response (relapse, partial responder or null responder). The differences between TPR and PR, and between BPR and PR reached statistical significance as reported by the OR 95 % CI. The comparison between TPR and BPR did not reach statistical significance (overlap of the OR 95 % CI).
Adverse events of grade 3-4 were derived from the clinical summary of safety of the different clinical trials, without distinguishing in TN and TE patients. It was assumed that boceprevir has the same adverse events as telaprevir (see Table 3 ).
Cost and Utility Estimates
Direct costs and indirect costs outside the healthcare system, such as the costs incurred as a result of loss of productivity and utilities of HCV patients, were retrieved from a Dutch cross-sectional [43, 44] survey with 3 years' patient chart data collection in 134 adults recruited in one university hospital, Erasmus University Medical Center (EMC). They had mild HCV (F1-2, n = 63), moderate HCV (F3-4, n = 31), cirrhosis (n = 23), decompensated cirrhosis (n = 4) and liver transplantation (n = 13). Inclusion criteria were: diagnosis and/or previous treatment for HCV Genotype 1, regular care at EMC, documented resource data, signed informed consent and age [18 years old. Patients were excluded if they participated in an RCT. Average age was about 56 with 30 % of the participants being males. The Liver Disease Symptom Index (LDSI) [45] , EuroQol-5D (EQ-5D) [46] , Short Form-Health and According to the Dutch guidelines, the societal perspective was chosen [24] with annual costs from the year 2011. Medication costs were derived from the Pharmacotherapeutical Compass (Farmacotherapeutisch Kompas) [51] . Outpatient visits, day care and hospital admissions unit costs came from the Dutch Cost Manual (2010) [23] , corrected for inflation (1.1 %) to the 2011 level [52] . Costs for hospitalisation and general laboratory and virology tests came from the Dutch Healthcare Authorities (CVZ, NZA) [53] whereas imaging procedures and surgical interventions were provided by the EMC. The mean hourly wage specific for gender and age was used to estimate indirect costs [47] according to the Dutch guidelines [24] , using the friction cost method (period: 3 months).
The weekly drug cost for PR was €181, €2,010 for telaprevir and €754 for boceprevir [54] . Overall, health state costs incorporated medication cost, cost of tests and monitoring costs (Table 4) .
The costs of adverse events were estimated by three Dutch experts. Rash, pruritus, nausea and diarrhoea cost, in total, between €32 and €40 per patient. The cost of treating an anaemic episode with a blood transfusion is estimated at €712 and €5,036 when using erythropoietin.
The utilities before and after treatment with SOC were derived from the EQ-5D, using the Dutch tariffs [55] . EQ-5D is the standardised instrument used to measure a health status and, in turn, a health outcome [56] . Decrease in utility associated with receiving anti-viral treatments came from ADVANCE [14] and REALIZE [16] RCTs, where EQ-5D was directly measured alongside the trials: -12.3 % if the patient is treated with PR and -11.4 % if treated with TPR and BPR. A utility decrease of 14.0 % for PR, 16.3 % for TPR or BPR, respectively, was applied for TE patients.
Annual discounting of 4 % (costs) and 1.5 % (outcomes) [24] was applied according to the Dutch guidelines.
Sensitivity Analysis
Deterministic sensitivity analysis (DSA) was performed to explore the sensitivity of the base case ICER to input parameters by varying each key parameter, within ranges reflecting possible parameter values, while holding all others constant. DSA determined if the model results were sensitive to the uncertainty in the value of any given model parameter and the degree of that sensitivity.
Sensitivity analyses were conducted on the following variables:
(a) Transition probabilities from mild to moderate and from moderate to cirrhosis (b) Comparative effectiveness ORs for SVR rates (c) Utilities (d) Health state costs (e) Discount rates for outcomes and costs Probabilistic sensitivity analyses (PSA) (N = 1,000) were conducted to estimate ICER 95 % CI. Each estimate was associated with a distribution function (available in Post-liver transplant Death 0.057 [28] electronic supplementary material) and a second-order Monte-Carlo simulation was conducted.
Results
Adding telaprevir or boceprevir to PR led to additional effects in life-years gained (LYG) and quality-adjusted life-years (QALYs) compared with PR (Table 5) , both in TN and TE patients. TPR led to more effectiveness than BPR, both in TN (0.12 LYG and 0.26 QALYs) and TE patients (0.35 LYG and 0.71 QALYs). Treatment strategy costs are reported in Fig. 2 . TPR for TN patients costs €67,956, the total drug cost of €30,080 being the main cost driver. BPR costs €75,251 with a total drug cost of €32,941 being the main cost driver as well. PR costs €67,534 with a drug cost of €11,585. The drug cost of BPR is the highest compared with that of TPR and PR, and also the non-drug cost was higher with BPR, making the total costs with TPR lower than BPR and only slightly higher than PR, as a result of savings in resource utilization.
TPR resulted in lower total costs (€89,500; €81,207, respectively, in all TE patients and 'partial responders and relapsers') compared with PR (€97,319; €94,039) and BPR (€107,614, €97,356). Higher SVR gained by TPR resulted in savings (on non-drug medical and indirect costs) that offset its higher acquisition price in comparison with PR. Table 6 reports the cost-utility results.
In TE patients, TPR dominated BPR and PR (i.e., it was more effective and less costly). In TN patients, TPR economically dominated BPR and the ICER was €299/QALY gained (QALYG) when compared with PR.
DSAs were performed. Discounting and OR of TPR versus PR were the variables that mostly affected the results in TN and TE models. Nevertheless, the fact that the ICER never exceeded the €8,000/QALY value implied that TPR remained cost effective for values other than the basecase values (see Fig. 3 ).
PSAs were performed. The results of the PSAs are reported in Fig. 4 (TN) and Fig. 5 (TE) .
In TN, the probability of having an ICER lower than €6,000 per QALY is 95 % when comparing TPR with PR. The probability of TPR dominating BPR is 93 %.
The probability of TPR dominating PR reached 100 % in partial responders and relapsers, whereas the respective probability of TPR dominating over BPR was 99.9 %.
Discussion
In this lifelong HCV Genotype 1 Markov model, it was found that TPR yielded 1.12 additional QALYs over PR and 0.27 additional QALYs over BPR, in TN patients. Bigger QALY gains were found in TE patients (1.63 QALYs) when comparing TPR and PR and when comparing TPR and BPR (0.69). As reported by our sensitivity analysis, the better TPR SVR rate (estimated by head-tohead RCTs and MTC) is one of the major drivers of the QALY gains. Even though the unit price of telaprevir was higher than PR and boceprevir, the total cost dedicated to treat a HCV patient over a full life was found to be lower with telaprevir than PR and BPR, in TE patients. In TN patients, the overall cost of treatment with TPR was less than with BPR and the ICER was €299/QALYG when compared with PR, a value that would be viewed as very cost effective in most of the Western developed countries. Being more effective in terms of SVR rate in TN and TE patients, TPR is likely to generate direct and indirect cost BPR boceprevir-peginterferon-ribavirin PR peginterferon-ribavirin, TPR telaprevir-peginterferon-ribavirin savings. Therefore, TPR dominates BPR and TPR is a very cost-effective alternative. The current study was based on a meta-analysis performed by Cure et al. [34] comparing telaprevir and boceprevir. In the meantime, three other papers were published on this comparison [57, 59] , but the outcomes differ from the ones published by Cure et al. Cooper et al. conclude there is no difference in effects, either for TN or for TE patients [57] [60] . Fifth, the use of relative risk as a measure of relative treatment effect is uncommon for indirect comparisons, instead OR could be used. A second study by Cooper et al. [58] is an improvement of the abovementioned publication and reports OR using a Bayesian technique. Still, they report a similar effect for telaprevir and boceprevir, because some of the criticism remains in their second study.
A third meta-analysis comparing telaprevir and boceprevir was provided by Kieran et al. [59] . They conclude that effects are similar, only reporting a difference in former relapsers where telaprevir is more effective. The most relevant points of criticism on the study of Kieran et al. overlap with the ones described for Cooper et al. Regimens not included in final labels were included, data of nonidentical treatment arms was pooled and null responders of telaprevir trials were included.
Our results are in line with a recent publication [61] where TPR and BPR were also considered as cost-effective alternatives to PR for the treatment of TN patients (only). Cammà et al. [18] reported, for Italy (2011 Euros), an acceptable ICER in comparison to PR (BPR €7,520/ QALY; TPR €10,755/QALY) while we reported a lower ICER when comparing TPR with PR. This could be explained by notable differences between the two models: (i) our time horizon is lifelong instead of 20 years; (ii) BPR boceprevir-peginterferon-ribavirin, LY life-years, LYG lifeyears gained, PR peginterferon-ribavirin, QALYs quality-adjusted life-years, QALYG quality-adjusted life-years gained, TE treatmentexperienced, TN treatment-naïve, TPR telaprevir-peginterferonribavirin Fig. 2 Total treatment cost in TN patients, all experienced, partial responders and relapsers, societal perspective. BPR boceprevir-peginterferonribavirin, PR peginterferonribavirin, TE treatmentexperienced, TN treatmentnaïve, TPR telaprevirpeginterferon-ribavirin much higher costs (from USA) were used for HCV drugs; (iii) discount rates are different; (iv) we included indirect costs; (v) we applied Dutch tariffs on EQ-5D instead of using the Health Utility Index (HUI) and they consequently used lower values in terms of utilities; (vi) the authors did not perform a comparison between TPR and BPR. Some of the differences are important drivers of the models and therefore explain the higher ICER of TPR over PR. However, our meta-analysis suffers from some limitations: the number of trials is limited (e.g., three RCT for the TE patients) and there was variability in the participating trials, although heterogeneity was not reported, statistically. This model is an adaptation of a model validated by SHPIC and CADTH. Adaptation to the Dutch environment was carefully conducted: (i) participation of Dutch experts in the model adaptation; (ii) resource utilisation data collection at EMC, an academic Dutch hospital; (iii) use of Dutch EQ-5D tariffs applied to quality-of-life data collected for Dutch patients; (iv) reference to the Dutch guidelines for conducting health economics evaluation; and (v) application of Dutch mortality data. However, at the time of the model adaptation, we hadn't found Dutch data enabling us to feed the probability transition matrix and therefore we used the best available international evidence in terms of SVR estimates (RCTs); we used MTC for indirect comparisons (a well accepted technique by health technology agencies). Complete anchoring to Dutch epidemiological data was, as such, not possible but we adapted the model to the Netherlands in the best possible way. Lastly, full sensitivity analyses were conducted and PSA demonstrated that the probability of not being cost effective at a €20,000/QALY threshold was very low. Additionally, similar conclusions were shown with a more recent study of Cammà et al. [19] in TE patients, where TPR dominates or is cost effective compared with BPR.
The choice for a cohort-based model over a microsimulation model was mainly driven by clinical data availability. Whereas data related to age and gender were available from the clinical trial, SVR related to, for example, viral load and body mass index were not. The clinical trials were not powered to study differences based on these subpopulations. We opted not to add additional uncertainty to the model, given that the results in the general hepatitis C population were clear and robust. A microsimulation model could have been of use to search for subpopulations in which the intervention could be of interest in case this interest was not found in the general population. In terms of model structure, some options could have been considered. Liu et al. [61] reported that combination therapy significantly reduced the risk of all-cause mortality (hazard ratio 0.42, 95 % CI 0.34-0.52). Although this information was not available at the time of the model adaptation, the compared strategies did not demonstrate any differential impact on overall mortality. However, patient life expectancy would have been longer, increasing the QALY benefit of telaprevir and, therefore, our approach remains conservative.
The transition probability from cirrhosis to decompensated cirrhosis after SVR was fixed at zero in the base-case scenario as requested by the three consulted Dutch experts. When using 3.9 % (i.e., the same transition probability in case of cirrhosis without SVR), TPR remained cost effective or dominant (example compared with PR ? €333, ?1.22 QALY) in all the scenarios.
The indirect costs for patients having achieved SVR were fixed at zero, hypothesizing that these patients would be able to manage their medical care without impacting on their work productivity, a fair assumption. When these indirect costs were put at the level of a patient with liver transplantation, TLR remained dominant over BPR, cost saving being -€21,541. Lastly, when the indirect cost of mild hepatitis equaled the indirect costs of moderate hepatitis, TLR remained cost saving in comparison with BPR (-€21,630).
This model did not address the use of IL-28B guided therapy. The MTC performed was solely aimed at comparing efficacy between BOC and TVR. Further, because the MTC was based on limited studies, it therefore did not In terms of prescribing, it is worth noticing that TPR dominates BPR in all populations and PR in TE patients. This means that TPR prescriptions, at a population level, are likely to deliver a higher level of effectiveness with no HCV societal budget increase.
To conclude, TPR in the Netherlands appears to be a cost-effective alternative to PR in TN patients and is dominating in TE patients. BPR and TPR are both beneficial over PR and are both clinically useful in that respect, but telaprevir had some advantages over boceprevir, mainly because of higher SVR rates, which made TPR the most cost-effective choice. Prescribing TPR may result in benefits to the Dutch HCV population at an acceptable societal cost. Cost -effectiveness plane TPR versus BPR 
